Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04612062 | A First-in-Human Study of CEE321 in Adult Subjects | PHASE1 | COMPLETED | 28 | — | — | Feb 27, 2020 | May 16, 2021 | Oct 28, 2022 | 3 | United States, Japan |
| Arm | Type | Description |
|---|---|---|
| Healthy Subjects (Part A) | EXPERIMENTAL | CEE321 0.2% (3 mg/cm2) topical cream b.i.d. |
| Atopic Dermatitis (Part B) | EXPERIMENTAL | CEE321 0.2% (3 mg/cm2) topical cream b.i.d. |
| Name | Type | Description |
|---|---|---|
| CEE321 | DRUG | CEE321 administered to all subjects |
Key inclusion Criteria for Healthy Subjects (Part A) * Written informed consent * Able to communicate well with the investigator to understand and comply with the requirements of the study, including skin biopsies * Healthy male and female subjects aged ≥18 and ≤ 65 years * Able to comply with requ...